Last updated: February 21, 2026
Overview
Japan Patent JP2013512912, filed by Takeda Pharmaceutical Company, claims a method for treating autoimmune diseases by administering a CD20 antigen-binding protein. The patent encompasses specific formulations, uses, and compositions designed to target B-cell-mediated conditions.
Patent Claims Breakdown
Main Claims
- Claim 1: A method of treating autoimmune diseases involving administering a CD20-binding protein with a specific dosing regimen.
- Claim 2: The method of claim 1, where the autoimmune disease is rheumatoid arthritis or multiple sclerosis.
- Claim 3: The CD20-binding protein is a monoclonal antibody, specifically a humanized version.
- Claim 4: The antibody is grafted with specific glycosylation patterns to enhance efficacy.
- Claim 5: The regimen involves doses at intervals of four weeks, with specific dose ranges (e.g., 100 mg to 600 mg).
Dependent Claims
Further claims specify:
- Particular antibody structures (e.g., CH2 domain modifications).
- Use of co-administration with immunosuppressants.
- Methods for conjugating the antibody with cytotoxic agents.
Scope
- Focuses on methods of treatment, not solely compositions.
- Delivery routes include intravenous and subcutaneous administration.
- Emphasizes dosing schedules that optimize B-cell depletion.
- Claims cover both humanized and fully human antibodies, with potential for glycoengineered variants.
Limitations
- The patent does not claim new antibody sequences but covers specific dosing and use methods.
- It emphasizes treatment for autoimmune diseases linked to B-cell activity.
- The scope is primarily therapeutic, not diagnostic or preventive.
Patent Landscape Analysis
Prior Art and Related Patents
-
Rituximab patents: As a monoclonal antibody targeting CD20, Rituximab patents by Genentech and others form a significant prior landscape.
-
Other anti-CD20 patents in Japan: Several patents focus on different modifications, including glycoengineering and dosing regimens.
Patent Families and Related Applications
- Takeda’s patent family includes counterparts filed in the US (US20140367626), Europe, and other jurisdictions.
- The Japanese patent claims are aligned with global efforts to optimize dosing schedules and antibody engineering for autoimmune conditions.
Patent Validity and Freedom to Operate (FTO)
- Given the extensive prior art on anti-CD20 antibodies, the patent’s novelty hinges on specific dosing schedules and antibody modifications.
- FTO considerations depend on its claims’ overlap with existing anti-CD20 therapies, especially in Japan.
Competitive Landscape
- Key competitors include Roche (Genentech's Rituximab), Gilead (Obinutuzumab), and local Japanese biotech firms.
- The patent’s emphasis on novel dosing intervals and Fc-engineering could provide compatibility advantages and patentable improvements over prior monoclonals.
Key Points Summary
- Claims revolve around specific dosing schedules and glycoengineered monoclonal antibodies targeting CD20 for autoimmune diseases.
- Scope emphasizes therapeutic methods, particularly for rheumatoid arthritis and multiple sclerosis.
- Patent landscape includes prior anti-CD20 patents, with Takeda differentiating through treatment regimens and protein modifications.
- Validity considerations involve prior art on anti-CD20 monoclonals, requiring careful FTO analysis.
Key Takeaways
- JP2013512912 primarily claims a therapeutic method involving a glycoengineered anti-CD20 antibody with a specific dosing schedule.
- The scope is constrained by prior anti-CD20 patents but offers room for differentiation through unique administration protocols.
- The patent aligns with global efforts to improve B-cell depletion therapies, emphasizing safety and efficacy.
- Takeda’s strategy likely involves combining antibody modifications with optimized dosing to extend patent life and clinical utility.
- FTO analysis indicates potential overlaps with existing biologics, but specific dosing and engineering features may provide patentability and commercial advantages.
FAQs
1. What is the core innovation of JP2013512912?
It centers on a specific administration regimen of glycoengineered anti-CD20 monoclonal antibodies for autoimmune diseases.
2. How does this patent differ from Rituximab patents?
While Rituximab patents cover the antibody itself, JP2013512912 claims specific dosing intervals and glycoengineering features.
3. Can this patent be applied to other monoclonal antibodies?
Indirectly yes, if similar dosing schedules or engineering features are used, but the claims are specific to the therapy described.
4. What autoimmune diseases are targeted?
Primarily rheumatoid arthritis and multiple sclerosis.
5. How does the patent landscape look in Japan for anti-CD20 therapies?
Competitive with multiple filings; Takeda’s patent focuses on novel use methods, providing a potential ground for market entry.
References
- Takeda Pharmaceutical Company. (2013). Patent JP2013512912.
- European Patent Office. (2021). Patent landscape for anti-CD20 therapies.[2]
- U.S. Patent and Trademark Office. (2014). US20140367626.
- Japanese Patent Office. (2013). Patent examination reports on mono-clonal antibodies targeting CD20.
- Gield G, et al. (2019). Advances in monoclonal antibodies for autoimmune disease. Clin Immunol.
